MedChemWatch
Monthly Newsletter January 2024

WELCOME BY THE NEW EFMC PRESIDENT, LUC VAN HIJFTE

Welcome to our first MedChemBioWatch for 2024!

As new EFMC President, it is my pleasure to take over the duty of Rui Moreira, thanking him again for his countless efforts in increasing the EFMC visibility, as well as supporting the existing and new activities which are affirming EFMC as a leading example towards our community and partners.

I start this year with motivation and enthusiasm, already looking forward to the collaboration we will have with the newly added National Adhering Organisations, the upcoming events which will mark our year, as well as the always expanding EFMC activities: the EFMC² Tandem Talk series, our sustainability initiative, new prizes and grants, and even more opportunities to network – both in presence and virtually.

These successes are only possible due to the involvement and perseverance of many members and collaborators, past and present, to whom I am thankful. I look forward to the many opportunities we will have to connect, collaborate, and achieve new milestones in our common goal of advancing medicinal chemistry and chemical biology.

Finally, on behalf of the EFMC, let me wish you a successful and healthy year.

Luc Van Hijfte
EFMC President

EFMC AWARDS & PRIZES – DEADLINE IS APPROACHING!

The deadline to apply for one of the 2024 EFMC Awards or Prizes is quickly approaching!

The Awards and Prizes will be presented at the XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024) to be held in Rome, Italy on September 1-5, 2024.

Nomination deadline is January 31, 2024 !

The Award will be given for outstanding achievements in scientific research including contributions to the development of international organisational structures in Medicinal Chemistry and Chemical Biology.

To acknowledge and recognise outstanding research in the field of Medicinal Chemistry in its broadest sense by a young scientist. This Award has been established with the support of UCB Pharma.

To encourage innovation and investigation in technological development related to drug discovery, this Award, established with the support of the Prous Institute, will be given for the discovery, evaluation, or use of new technologies.

Prizes

To acknowledge and recognise outstanding young medicinal chemists and chemical biologists (≤ 12 years after PhD) working in European industry and academia.

To recognise excellence and merits at the early stage.

SUBMIT YOUR ABSTRACT FOR ORAL COMMUNICATION


EFMC HONORARY FELLOWS – DEADLINE IS APPROACHING!

This life-long title and associated medal aim to recognise individuals who have provided outstanding support to the EFMC and contributed to strengthening the position of medicinal chemistry, chemical biology, or related fields in Europe.

Nominations can be submitted until January 31, 2024, and should include:

  • Brief curriculum of the nominee
  • Statement of the documented facts supporting the nomination, summarizing scientific achievements and support of EFMC activities (maximum two pages)
  • Two seconding nomination letters

Self-nominations are not accepted. There are no age restrictions, and nominees may have an academic or industrial background. Nominees should be European residents or have spent a considerable proportion of their career in Europe.

The award ceremony will take place during the opening of the XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024) to be held in Rome, Italy on September 1-5, 2024. Appointed Honorary Fellows will be invited to attend the meeting and receive their award on stage.

More information and nominations on www.efmc.info/honorary-fellows.

LITERATURE SPOTLIGHT

The “literature spotlight” section of the newsletter will bring you a summary of recently published research in a concise and accessible way. Multiple thematics from different journals will be highlighted thanks to the valuable contribution of members of the EFMC working groups.

This contribution will focus on the recently published article on “De novo development of small cyclic peptides that are orally bioavailable” by Merz M.L. et al., published in Nat Chem Bio.

This article from the Heinis group at EFPL delves into the potential of cyclic peptides as targeted therapies for challenging diseases, emphasizing their high specificity and affinity. Despite their promise, the oral administration of most cyclic peptides faces limitations due to rapid digestion and poor gut absorption, hindering their therapeutic efficacy. This study presents a novel approach centered on combinatorial synthesis and screening methods aimed at developing orally available cyclic peptides.

Addressing the challenges of targeting specific proteins using traditional oral small molecules, cyclic peptides emerge as a promising solution due to their capacity to bind challenging targets while being suitable for oral administration. Although certain naturally derived peptides have been transformed into oral drugs, the majority are either too large or unstable for oral use.

Factors such as molecular weight, hydrogen bond donors, and polar surface area significantly influence the oral availability of peptides. Strategies like N-methylation and specific conformational adaptations exhibit potential in enhancing oral bioavailability.

The study details a methodology involving combinatorial synthesis and screening in microwell plates to generate a library of 8,448 cyclic peptides. It explores hurdles encountered with various cyclization chemistries and devises a two-step synthesis strategy to produce more stable thioether-cyclized peptides.

Researchers adapted their screening methods to evaluate stability and membrane permeability, resulting in the identification of a cyclic peptide with 18% oral availability in rat models. This work introduces synthesis and screening tools applicable across diverse targets, potentially facilitating the development of selective inhibitors or activators for enzymes, receptors, or ion channels that are considered hard to tackle.

Read the article.

EFMC-YSN WEBINAR - CHEMISTS IN INDUSTRY ACROSS BORDERS

A joint SCI Young Chemist' Panel and EFMC Young Scientists Network collaboration aiming at exploring the journeys of five early-career researchers working abroad in industry, and tackling topics such as relocation support, cultural integration, and advice on how to transition from academia into industry and accelerate your career trajectory.

This free webinar will provide delegates an open forum to pitch questions to our diverse speaker line-up, while learning useful tips and tricks to successfully prepare for careers abroad.

The event will take place on January 23 from 14:00 to 15:30. More information and registration here

Programme 

  • 14:00 | Welcome & Introduction 
  • 14:05 | Presentation of the Speakers 
    • Stefano Levanto (Charles River Laboratories, United Kingdom)
    • Laureline Morin (AstraZeneca, United Kingdom) 
    • Andrew Shouksmith (Selvita, Poland)
    • Anika Tarasewicz (Sanofi, Germany)
    • Erika Tassano (Novartis, Switzerland)
  • 14:30 | Round Table Discussion 
  • 15:30 | End of the Webinar

2nd EFMC² TANDEM TALKS

EFMC² Tandem Talks, jointly organised by the EFMC and the EFMC Computational Chemistry Initiative (EFMC²), are designed to give you real life insights into how medicinal and computational chemists can drive projects together.  The tandem talks feature a balanced perspective from both sides.

The second edition will take place on February 15 from 16:00 to 17:00 CET. Judith Günther (Bayer) & Léa Bouché (Roche) will deliver a lecture on “BAY-069, a Novel (Trifluoromethyl)pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe” before joining the round table discussion to interact with the attendees.

More information and registration on www.efmctandemtalks.org.  

MEET GIANLUCA SBARDELLA, UNIVERSITY OF SALERNO, ITALY

In this edition, our MedChemBioConversations is with the current EFMC Secretary, Prof. Gianluca Sbardella from the University of Salerno, Italy.

Get to know him better by reading the interview below:

How did you get interested in Medicinal Chemistry?

When I was in high school, I read “The Periodic Table”, a short story collection by the Italian chemist, partisan, writer, and Jewish Holocaust survivor Primo Levi, named after the periodic table in chemistry. Among the others a passage in the short story “Iron” caught my attention and fascinated me: “the nobility of man, acquired in a hundred centuries of trial and error, lay in making himself the conqueror of matter, and that I had enrolled in chemistry because I wanted to remain faithful to this nobility. That conquering matter is to understand it, and understanding matter is necessary to understanding the universe and ourselves: and that therefore Mendeleev's Periodic Table, which just during those weeks we were laboriously learning to unravel, was poetry, loftier and more solemn than all the poetry we had swallowed down in liceo; and come to think of it, it even rhymed!”. In that moment I decided that chemistry should be my own path. Within this context, medicinal chemistry was a natural choice because I have always been fascinated by the chemistry and biology interface, in particular the capability to affect human diseases. To me, medicinal chemistry gives you superpowers!

Where and when did you obtain your PhD diploma?

It was back in 1997, at the University of Rome “La Sapienza”, under the supervision of prof. Marino Artico. My PhD project was focused on the development of 2-alkoxy- and 2-alkylthio-6-arylmethyl-4-oxopyrimidines as a new class of potent non-nucleoside HIV-1 Reverse Transcriptase inhibitors. After the PhD, I spent postdoctoral stints at the Drug Chemistry Center of Italian National Research Center (Rome, 1 year), Italian National Institute of Health (2 years), University of Rome "La Sapienza" (1 year), University of Siena (1 year) before joining the Department of Pharmacy of the University of Salerno, Italy, as an assistant professor. Three years later, I spent a sabbatical period (1 year) as a visiting professor at the Department of Chemistry and Biochemistry of the University of California Los Angeles (UCLA), in the group of Michael E. Jung.

What are your current research interests?

The main interest of my research group (Epigenetic Med Chem Lab, EMCL) is the development of chemical probes for the study of protein targets responsible (directly or indirectly) of epigenetic modifications (KATs, KMTs, DNMTs, PRMTs, KDMs, bromodomain, MBT, Tudor) or of proteins regulated by epigenetic processes (e.g., LINE-1 RT), taking advantage of a multidisciplinary approach combining synthetic organic chemistry, medicinal chemistry, chemical biology, biochemistry and biophysics. But, of course, we also have running projects on other topics outside the epigenetics field.

How would you explain what your research area is to non-scientists?

There are quite a lot of beautiful examples that can be used to better explain epigenetics. In general, I use a musical metaphor. DNA is often considered as if it’s a template, like a mold for a car part in a factory, popping out thousands of identical car parts unless something goes wrong in the process. But DNA isn’t really like that. It is more like a musical score, that could be played in quite different ways like, for example, are the interpretations of “What a wonderful world” by Louis Armstrong and Joey Ramone. And how the DNA score is played depends on epigenetic mechanisms. In my group, we develop chemical tools for studying such mechanisms.

What do you like best about your work?

The freedom to work on what interests me most, coming up with new research ideas, designing experiments and potential molecules, working with intelligent and enthusiastic early career researchers who are willing to embrace exciting new approaches, mentoring students. And I really love the multidisciplinary nature of our research. 

What kind of tasks does your work involve?

It’s been several years since I worked in the lab and it’s a pity as it was the real fun. My current tasks include teaching, writing papers, and finding money for research by writing national and international grant applications. Mentoring PhD students and postdocs and guide them towards the research goals is another important task. And (unfortunately) administrative/institutional tasks also occupy a large part of my time, much larger than I wish.

In science being a good communicator is of high importance, not just for teaching. Curiosity is an essential skill but knowledge, creativity (with the ability to repeatedly generate good ideas), critical thinking (and seeing underlying principles behind data sets and deriving new concepts and principles from them), commitment, persistence, social, communication, and team leader skills as well as intuition are also quite important. 

How many PhD students and postdocs do you currently supervise? Are you currently looking for a new PhD student or a postdoc?

My research group has shrunk a little bit during the last few years because of the COVID19 pandemic. Currently it consists of around 20 people (including assistant and associate professors) and there are 4 PhD students and 3 postdocs, besides many undergraduate students. The group will expand again in the future and applications by talented and motivated candidates with the right background and passion are always welcome.

How would you describe yourself as a supervisor?

I care about the progress of my students and try to push them as much as I can for success. I encourage them to think independently. Good science needs the air of freedom to explore ideas and to be creative, and I give my students and postdocs the required room. I believe that a student that knows the bigger picture is more motivated to accomplish her/his goals and therefore I constantly share with my students the primary goals and future directions so they could choose where to take their projects to.

The social atmosphere in the group is also of high importance.

Supervising students goes beyond providing scientific guidance. Mentoring is crucial for career development, and I always try to encourage and motivate students at a personal level when problems arise during their projects.

What do you consider your greatest achievement in your scientific career?

It is difficult to name one, because I’m very proud of all the research work we have done. Probably one of the most important achievements was the discovery of the first inhibitor of the Tudor-domain-containing protein Spindlin1 (SPIN1), capable of engaging the protein in cells, blocking its ability to 'read' H3K4me3 marks and inhibiting its transcriptional-coactivator activity. Other important ones are the development of an inhibitor of the retrotransposon LINE1 reverse transcriptase which also induces apoptosis in a cell-density-dependent manner and antagonizes tumour growth in animal models, the development of a positive modulator of the lysine acetyltransferase PCAF able to selectively regulate the extinction of conditioned fear, the identification of a novel selective and cell-active chemotype for G9a/GLP inhibitors, based on the underinvestigated 2-alkyl-5-amino- and 2-aryl-5-amino-substituted 3H-benzo[e][1,4]diazepine scaffold, the identification of an allosteric inhibitor of the acetyltransferase p300, and the identification of the first potent PRMT7/9 inhibitor.

But I am also very proud of the career achievements of my former graduate and PhD students, both in academia and industry all over Europe.

 What are the features of a successful PhD student or postdoc?

Curiosity and motivation to learn new topics and techniques together with being passionate about the research project (and science in general) are certainly the most important, even more than having an outstanding knowledge of organic and medicinal chemistry. But do not misunderstand me: cutting-edge research is highly challenging and a strong science education with well-developed laboratory skills is necessary to start tackling significant challenges. Also, I would be lying if I didn’t say that being hard-working is a crucial feature, as well as having a critical mindset and being perseverant and not giving up when things do not work (the first, second, and even a third time). Remaining up-to-date by reading literature, going to conferences, and talking to people are also important together with team spirit, collaboration and good communication skills.

What advice would you give to someone who wants to know more about your field? 

I am pretty sure that most (if not any) medicinal chemists/chemical biologists, both in academia and industry, are happy to discuss science and career development. Personally, I am. So, reach out to anyone who can tell you more about medicinal chemistry/chemical biology and don’t be afraid to ask. There are no silly questions.

It is critical to always be open-minded, combining the deep experience in the field with a global scientific perspective and never hesitate to embrace new developments and new fields. And I would love if academia and industry could work together to train the next generation of medicinal chemists.

Have you experienced any unfair situations during your scientific career? How would you advise scientists facing similar situations?

I guess that anyone has perceived something unfair in her/his own career, for instance reviews of papers and/or grant applications or by company-internal Boards, and I’m not an exception to this. Of course, they are annoying, but in my experience not being too annoyed and trying to take such situations easy helps. I try not to think about the things I didn’t get (and why) and focus and appreciate the things I accomplished

What is the most embarrassing thing you have done in the lab while doing experiments, e.g., explosions?

There are two episodes, both dated back to my period as an undergraduate student and both related to the use of a rotavap. In the first, I forgot to use the metal (or Keck) clip to secure the flask and before reaching the required vacuum, the flask (a 1000 ml one) fell into the rotavap bath and filled up with the bath water. I had to extract (and purify again) my compound from the whole volume. In another situation, I did not notice that the glass joint of the neck of the flask was not completely clean. Of course, after the evaporation of the solvent it was stuck on the rotavap and when I forced it to come off it cracked and ripped my thumb open. It needed a six-stiches suture at the hospital, and I still have the scar (32 years later).

What are your recommendations for a book, podcast, website, blog, YouTube channel or film?

Chemistry is usually represented as a threat or in a negative way in movies. Nonetheless, in my lessons I often quote some specific movie scenes to let students visualize (or better remind) something: for example, the scene from Pulp Fiction of the intracardiac injection of adrenaline by Vincent Vega (John Travolta) to revive Mia Wallace (Uma Thurman) after her heroin overdose, or the story in Awakenings (from the book of the same name by Oliver Sacks) of the repositioning and off-label usage of L-DOPA by Dr. Malcolm Sayer (Robin Williams) to “awake” Leonard Lowe (Robert De Niro) from encephalitis lethargica. Besides The Periodic Table by Primo Levi (and also all his other books) and Awakenings by Oliver Sacks, another book I would recommend is Perfume by Patrick Süskind, with interesting details about olfactory perceptions, extraction techniques, and the chemistry of making perfumes.

Regarding blogs, everyone working in medicinal chemistry should read Derek Lowe’s ‘In the pipeline’ (https://blogs.sciencemag.org/pipeline/) and Dan Erlanson’s ‘Practical Fragments’ ( http://practicalfragments.blogspot.com/) blogs.

As websites I would recommend Drug hunter (https://drughunter.com/) and Endpoints news (https://endpts.com) and, above all, the EFMC website and YouTube channel, in particular the section related to the slide decks and webinars by the Best Practice in Medicinal Chemistry Working Group (https://www.efmc.info/best-practices). 

Which scientist do you admire the most and why?

There are many of them. In my opinion, Dave Evans was one of the most influential scientists in chemistry, who brought together an incredible collection of researchers and inspired many others (including me). Another fantastic scientist was David C. Allis. Not only he gave an amazing contribution to chromatin biology and epigenetics research, but he was known and loved for being a great mentor and a very lovely person. 

Quite often in my talks and in my lessons, I  quote a sentence by Stuart Schreiber: “There should be no problem with biology driving science unless perhaps you happen to be a chemist!”. And, in fact, he and his way to approach biology from a chemist's perspective are of great inspiration for me (together with K.C. Nicolaou, Stuart Schreiber coined the expression “chemical biology”). And I really admire all the colleagues in academia who succeeded in developing a compound that finally ended to become a FDA/EMA approved drug. Two examples are Roberto Pellicciari and Michael Jung.

What would you expect to be the next major breakthrough in medicinal chemistry?

Induced protein proximity is already a reality and I expect than various drugs deriving from this approach will be approved in the near future. Also, I am pretty sure that besides the few examples already approved, many other therapeutics targeting proteins involved into epigenetic pathways will find their way to the clinical.

EFMC SESSSION AT THE 9th EUCHEMS CHEMISTRY CONGRESS

The Institute of Chemistry of Ireland (ICI) is delighted and honoured to be organising the 9th EuChemS Chemistry Congress (ECC-9), to be held in Dublin, Ireland, from 7th – 11th July, 2024.

The 9th EuChemS Chemistry Congress will have an exciting scientific programme with world-leading plenary speakers, invited speakers and short oral presentations, supplemented with a series of poster presentations, focused around eight scientific themes:

  • Energy, Environment and Sustainability
  • Physical, Analytical and Computational Chemistry
  • Advances in Synthetic Organic Chemistry
  • Chemistry Meets Biology for Health
  • Catalysis
  • Supramolecular Chemistry
  • Nanochemistry/Materials
  • Education, History, Cultural Heritage, and Ethics in Chemistry

The EFMC is proud to contribute to the programme with a session on “The Potential of Electrochemistry to Power Drug Discovery”, with confirmed lecture of Prof. Phil Baran (The Scripps Research Institute, USA) and Prof. Kevin Lam (University of Greenwich, UK).

Oral and Poster Abstract deadline: January 15, 2024
Early bird registration: March 8, 2024

More information and registration: https://euchems2024.org/

NEWS FROM THE BIOLOGICAL AND MEDICINAL CHEMISTRY SECTOR (BMCS) OF THE ROYAL SOCIETY OF CHEMISTRY (RSC)

The BMCS is happy to announce several upcoming events.

RSC-BMCS Conformational Design in Drug Discovery
7th March, 2024, GSK, Stevenage, UK
Registration is now open! Abstract submissions are now open!

Website: https://www.rscbmcs.org/events/conformationaldesign24/

Synopsis : Conformational Design has played a key role in the medicinal chemistry of small molecule clinical[AN1]  candidates over the last 20 years. A key learning from multiple projects supported by experimental free ligand NMR solution conformations and protein-ligand X-ray structures is that the bioactive conformation of potent ligands is highly populated in solution. Ligand rigidification has been particularly successful in the design of selective and potent protein-protein interaction inhibitors and is becoming an increasingly important approach for PROTACs, molecular glues and other new modalities. This new RSC-BMCS event aims at building a community that shares conformational design strategies, technologies, and successful case studies. It will complement other rational drug design events and promote more successful research into future medicines.

The BMCS Mastering MedChem VIII: 8th RSC-BMCS Symposium on Mastering Medicinal Chemistry
15th March, 2024, Burlington House, London, UK
Registration is now open!

Website: https://www.rscbmcs.org/events/mastermedchem24/

Synopsis: Mastering Medicinal Chemistry VIII is the latest in an ongoing series of conferences intended to provide expert advice and guidance to new practitioners in the field of drug discovery. It has been said that “there are two types of drug discovery programmes: those that hit serious problems and those that are going to hit serious problems”. Anticipating and preparing for such problems thus accelerates the delivery of new medicines: this event will feature presentations from experienced ‘drug-hunters’ in both industry and academia, who will talk about the challenges faced in modern drug discovery, and will share best practice common to all successful medicinal chemists.

RSC-BMCS 35th Symposium on Medicinal Chemistry in Eastern England
25th April 2024, GSK Conference Centre, Stevenage UK
Registration will be open soon!

Website: https://www.rscbmcs.org/events/mcee35/ 

Synopsis: Known colloquially as the “Hatfield MedChem” meeting, this is a highly successful, long-standing, one-day meeting that runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics at the forefront of drug discovery. The meeting aims to be informal and interactive, and is ideal for all those working in medicinal chemistry and drug discovery more widely.

RSC-BMCS Hot Topics: Covalent Drug Discovery 2024
16th May 2024, Virtual
Registration is now open! 

Website: https://www.rscbmcs.org/events/hottopicscdd24/

Synopsis: Covalent binding has emerged as a key strategy in contemporary drug discovery. This online, half-day meeting will bring together experts from both academia and industry to discuss recent advances in using covalent small molecules to target challenging protein targets. The BMCS Hot Topics online meetings are intended to highlight breaking areas of research in fields of science relevant to drug discovery. They will run as stand-alone half-day virtual events, 2-3 times per year. The programme will be targeted towards researchers working who would like to enhance their understanding of these nascent or developing fields.

 

ANNOUNCEMENT

EFMC ORGANISED EVENTS

February 15, 2024
Virtual Event
2nd EFMC² Tandem Talks

April 8-11, 2024
Utrecht, The Netherlands
EFMC-ACSMEDI Medicinal Chemistry Frontiers 2024

April 21-24, 2024
Oegstgeest, The Netherlands
18th EFMC Short Course on Medicinal Chemistry

September 1-5, 2024
Rome, Italy
XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024)

September 5-6, 2024
Rome, Italy
11th EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS 2024)

EFMC SPONSORED EVENTS

January 24-26, 2024
Orsay, France
SCF Chemical Biology Symposium 2024 – Chemistry meets Biology

January 28-February 1, 2024
St. Anton, Austria
4th Alpine Winter Conference on Medicinal and Synthetic Chemistry

JOB PORTAL

Scientist/Senior Scientist, Discovery and Lead Generation Chemistry, Monte Rosa Therapeutics, BASEL
Read more

Full Professor - Head of the Organic and Pharmaceutical Chemistry Dept, IQS School of Engineering. Universitat Ramon Llull, BARCELONA
Read more

Scientist Organic Chemistry / Chemical Biology, Bayer AG, WUPPERTAL
Read more

Scientist Chemical Biology / Cell Biology / Molecular Biology, Bayer AG, WUPPERTAL
Read more

Assistant Professor (Tenure Track), National University of Singapore, SINGAPORE
Read more

Postdoctoral Researcher, ETH Zurich, ZURICH
Read more

Associate Principal/Principal Scientist, Sygnature Discovery, NOTTINGHAM
Read more

Find us on social media

EFMC Facebook EFMC Twitter EFMC LinkedIn EFMC Instagram

EFMC